gossypol has been researched along with acenaphthenequinone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Feng, Y; Li, X; Liu, C; Qin, J; Song, T; Wu, Z; Xie, F; Zhang, Z | 1 |
| Chen, H; Li, X; Liang, X; Liu, C; Shen, X; Song, T; Wu, Z; Zhang, Z; Zhao, Y | 1 |
2 other study(ies) available for gossypol and acenaphthenequinone
| Article | Year |
|---|---|
Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach.
Topics: Acrylonitrile; Benzylamines; Binding Sites; Biomimetics; Blotting, Western; Cell Line, Tumor; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Molecular Structure; Myeloid Cell Leukemia Sequence 1 Protein; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Solubility; Structure-Activity Relationship; Thermodynamics | 2013 |
Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Tumor Cells, Cultured | 2013 |